Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07200128 · ClinicalTrials.gov registry record
A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
A clinical trial of Severe Alopecia Areata, sponsored by Pfizer.
- Completed
- Registry status
- 123
- Enrollment target
- 1
- Study location
NCT07200128: Completed study of Severe Alopecia Areata, sponsored by Pfizer.
NCT07200128 is a study of Severe Alopecia Areata that has completed, run by Pfizer. The registered enrollment target is 123 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07200128, a study of Severe Alopecia Areata, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 123 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a secondary analysis of the Adelphi Real World Alopecia Areata II United States Disease Specific Programmes database. This database contains data from a cross-sectional study capturing linked physician and patient survey data for dermatologists who treat alopecia areata and patients diagnosed with alopecia areata in the United States. The retrospective analysis of these data will evaluate experiences of patients and dermatologists receiving/prescribing ritlecitinib for severe alopecia areata in the United States. Specifically, the study will describe characteristics of patients who received ritlecitinib for severe alopecia areata, including demographics, clinical characteristics at the time of starting ritlecitinib, and their alopecia areata-related treatment history. The study will also report dermatologist satisfaction with treatment and change in the patient's alopecia areata severity and disease activity from the start of ritlecitinib to different time points on treatment.
Conditions Studied
Interventions
- DRUG Ritlecitinib
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2025-05-30 |
What the finished NCT07200128 record still lists
NCT07200128 is an observational study that tracks outcomes without assigning an intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Severe Alopecia Areata appearing as the primary indexed condition, and to 1 intervention - of which Ritlecitinib is the first listed.
NCT07200128 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07200128 about?
NCT07200128 is a clinical study titled "A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings". This study is a secondary analysis of the Adelphi Real World Alopecia Areata II United States Disease Specific Programmes database. This database contains data from a cross-sectional study capturing linked physician and patient survey data for dermatologists who treat alopecia areata and patients di...
What is the current status of trial NCT07200128?
This trial is currently completed. The enrollment target is 123 participants. The study started on 2025-02-03. Estimated completion is 2025-05-30.
What conditions does trial NCT07200128 study?
This clinical trial studies the following conditions: Severe Alopecia Areata.
What interventions are being tested in trial NCT07200128?
The interventions under investigation include: Ritlecitinib (DRUG).
Who is sponsoring clinical trial NCT07200128?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07200128 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI